InspireMD(US:NSPR)2025-11-04 21:06Financial Performance - Total revenue for Q3 2025 increased by 39% to $2.5 million compared to $1.8 million in Q3 2024[3] - Gross profit for Q3 2025 was $864,000, up from $414,000 in Q3 2024, reflecting a favorable sales mix[4] - Net loss for Q3 2025 was $12.7 million, or $0.17 per share, compared to a net loss of $7.9 million, or $0.16 per share, in Q3 2024[9] - Cash and cash equivalents as of September 30, 2025, were $63.4 million, up from $34.6 million as of December 31, 2024[9] Revenue Breakdown - U.S. revenue for Q3 2025 was $497,000, while international revenue was $2.0 million, driven by the CGuard Prime launch and increased market penetration[3] Operating Expenses - Total operating expenses for Q3 2025 rose by 57% to $13.9 million, primarily due to increased headcount and infrastructure costs[7] Strategic Initiatives - The company raised $58 million in gross proceeds to support its commercial rollout and talent acquisition[2] - InspireMD aims to transform the carotid intervention market with a stent-first approach, indicating a strategic focus on innovation and market expansion[2] Operational Highlights - The company completed over 100 U.S. carotid procedures using the CGuard Prime system during the quarter[5] - InspireMD strengthened its leadership team by appointing Peter A. Soukas, M.D., as Chief Medical Officer[5]